respond so well to cannabis medications.
It’s because they have lower endogenous cannabinoid levels compared to matched controls.
The study, which was published in the medical journal Molecular Autism, involved analyzing the endocannabinoid serum rates among 93 patients with autism spectrum disorder (ASD) and compared them to controls. The researchers found that the children with ASD have “substantially lower” serum levels of anandamide, a primary endocannabinoid, as well as other compounds.
Israeli scientists have long been in the forefront of autism research, as well as other medical applications of cannabis. This has been a great help to the scientific community at large, who have found it challenging to gain a better understanding of autism among children. This condition spares no one, yet every autistic child is affected in a different way. For this reason, finding standard treatment options has been close to impossible. But cannabis is proving promising for autism.